Wayne Winegarden
Blog
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...
Commentary
The Medicare Bureaucracy Is Unnecessarily Putting Kidney Patients At Risk
The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore alternatives to face-to-face triage and visits.” The CDC has issued this recommendation to help contain the spread of the virus, protect healthcare workers from ...
Commentary
Expand Pharmacists’ Authority To Promote Access To Forthcoming COVID-19 Vaccine
Private pharmaceutical companies and the National Institutes of Health have outdone themselves. Thanks to the funding provided by the NIH, a Phase 1 clinical trial for a COVID-19 vaccine is underway. In separate efforts, Inovio, Sanofi, Vaxart, GlaxoSmithKline, and Johnson & Johnson are all developing potential vaccines. In total, “about 35 companies ...
Featured
NEW ISSUE BRIEF: Expanding Biosimilars Use Could Save Patients, Reduce Out-of-Pocket Costs By 17 Percent
Expanding the use of biosimilars to treat serious illnesses like cancer or auto-immune diseases could reduce a patient’s out-of-pocket costs by 17 percent, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the study “Biologics ...
Commentary
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Commentary
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Business & Economics
The SEC’s Proposed Rule Will Improve Transparency And Protect Investors
The complexity of the financial markets encourages people to support positions that would be unthinkable in most other situations. Such is the case with the Securities and Exchange Commission’s (SEC) proposed new regulations of proxy advisory firms. The SEC requires institutional investors (such as mutual funds and public pension funds) ...
Commentary
Price Controls Impose High Costs On Patients
Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Business & Economics
Eliminating barriers to entrepreneurship will help immigrants, poor
The United States is in the midst of the longest economic expansion on record. The U.S. economy has been growing for more than 10 years. The unemployment rate is near its lowest point ever. And yet, poverty continues to be persistent nationwide. Tens of thousands of people are homeless in ...
Blog
Lies, Damn Lies, and Drug Price Increases
As each new year begins, the increases in the list prices of drugs are announced. And, following these announcements, the political class complains that something must be done. This year, following the price announcements, Speaker Nancy Pelosi tweeted “Enough is enough” while Senator Grassley emphasized that a “call to action” ...
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...
The Medicare Bureaucracy Is Unnecessarily Putting Kidney Patients At Risk
The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore alternatives to face-to-face triage and visits.” The CDC has issued this recommendation to help contain the spread of the virus, protect healthcare workers from ...
Expand Pharmacists’ Authority To Promote Access To Forthcoming COVID-19 Vaccine
Private pharmaceutical companies and the National Institutes of Health have outdone themselves. Thanks to the funding provided by the NIH, a Phase 1 clinical trial for a COVID-19 vaccine is underway. In separate efforts, Inovio, Sanofi, Vaxart, GlaxoSmithKline, and Johnson & Johnson are all developing potential vaccines. In total, “about 35 companies ...
NEW ISSUE BRIEF: Expanding Biosimilars Use Could Save Patients, Reduce Out-of-Pocket Costs By 17 Percent
Expanding the use of biosimilars to treat serious illnesses like cancer or auto-immune diseases could reduce a patient’s out-of-pocket costs by 17 percent, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the study “Biologics ...
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
The SEC’s Proposed Rule Will Improve Transparency And Protect Investors
The complexity of the financial markets encourages people to support positions that would be unthinkable in most other situations. Such is the case with the Securities and Exchange Commission’s (SEC) proposed new regulations of proxy advisory firms. The SEC requires institutional investors (such as mutual funds and public pension funds) ...
Price Controls Impose High Costs On Patients
Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Eliminating barriers to entrepreneurship will help immigrants, poor
The United States is in the midst of the longest economic expansion on record. The U.S. economy has been growing for more than 10 years. The unemployment rate is near its lowest point ever. And yet, poverty continues to be persistent nationwide. Tens of thousands of people are homeless in ...
Lies, Damn Lies, and Drug Price Increases
As each new year begins, the increases in the list prices of drugs are announced. And, following these announcements, the political class complains that something must be done. This year, following the price announcements, Speaker Nancy Pelosi tweeted “Enough is enough” while Senator Grassley emphasized that a “call to action” ...
